bluuebunny/crossref_metadata_2025_split huggingface dataset:
Out-of-pocket costs associated with chronic respiratory diseases in Korean adults
Authors: Park Jun Su , Kim Bomgyeol , Kim Yejin , Lee Sang Gyu , Kim Tae Hyun 
Published: February 2024

Objectives Chronic respiratory diseases (CRDs) are a burden on both individuals and society. While previous literature has highlighted the clinical burden and total costs of care, it has not addressed patients’ direct payments. This study aimed to estimate the incremental healthcare costs associated with patients with CRDs, specifically out-of-pocket (OOP) costs. Methods We used survey data from the 2019 Korea Health Panel Survey to estimate the total OOP costs of CRDs by comparing the annual hospitalizations, outpatient visits, emergency room visits, and medications of patients with and without CRDs. Generalized linear regression models controlled for differences in other characteristics between groups. Results We identified 222 patients with CRDs, of whom 166 were aged 65 years and older. Compared with the non-CRD group, CRD patients spent more on OOP costs (238.3 USD on average). Incremental costs were driven by outpatient visits and medications, which are subject to a coinsurance of 30% or more and may include items not covered by public insurance. Moreover, CRD patients aged 50–64 years incurred the highest incremental costs. Discussion The financial burden associated with CRDs is significant, and outpatient visits and medications constitute the largest components of OOP spending. Policymakers should introduce appropriate strategies to reduce CRD-associated burdens.
Immunotherapeutic Properties of Dexmedetomidine on Pain Management and Cardiovascular Function in Videolaparoscopic Cholecystectomies: A Randomized, Two-Arm, Double-Blinded, Placebo-Controlled Trial
Authors: Silva Gustavo Nascimento , Brandão Virna Guedes , Perez Marcelo Vaz , Sobrinho Sandoval Lage , Villardi João Gabriel de Cerqueira Campos , Sacramento Priscilla Mendonça do , Ribeiro Luiz Claudio Pereira , Alvim Fiorelli Rossano Kepler 
Published: February 2024

Background Laparoscopy represented one of the most innovative surgical techniques approached in the surgery field. Dexmedetomidine association with general anesthesia promotes the response control to trauma by altering the neuroinflammatory reflex, provides better clinical outcomes in the postoperative period and reduces the excessive use of drugs with risk for addiction. This trial aims to evaluate the potential drug treatment of dexmedetomidine on organic function, with the targets in neuroinflammation, perioperative pain control and blood pressure measurements in a medium-sized surgical model. Methods Fifty-two patients were randomized in two groups: Sevoflurane and Dexmedetomidine – A (dexmedetomidine infusion [1 μg/kg loading, .2-.5 μg/kg/h thereafter]) vs Sevoflurane and Saline .9% - B. Three blood samples were collected at three times: before surgery, 4 to 6 hours after surgery and 24 hours postoperatively. The primary outcome was inflammatory and endocrine mediators dosage analisys. Finally, we evaluated pain and opioid use as secondary outcomes, also the hemodynamic values. Results In Dexmedetomidine group A, a reduction of Interleukin 6 was found during 4-6 hours after surgery. A reduction of IL-10 was noted in the measurement of its values 24 hours after the procedure, with statistical significance. Also, systolic and diastolic blood pressure, as well heart rate were attenuated, and there was a lower incidence of pain and opioid consumption in the first postoperative hour ( P < .0001) in the anesthetic recovery room. Conclusions Dexmedetomidine provided anti-inflammatory activity, sympatholytic effect and analgesia with cardiovascular safety. It reinforces the therapeutic nature of highly selective α2-adrenergic agonists when combined within anesthetic interventions.
Dynamic Computed Tomography of the Distal Radioulnar Joint Versus Magnetic Resonance Imaging in Detecting Foveal Tears of the Triangular Fibrocartilage Complex
Authors: Braig Zachary V. , Dittman Lauren E. , Amrami Kimberly K. , Kakar Sanjeev 
Published: February 2024

Background: Diagnosis of foveal triangular fibrocartilage complex (TFCC) tears remains difficult. The purpose of this study was to evaluate whether dynamic computed tomography (CT) of the distal radioulnar joint (DRUJ) has a higher sensitivity in detecting foveal tears of the TFCC when compared with magnetic resonance imaging (MRI). Methods: A database query identified all patients above the age of 18 years with suspected foveal TFCC injuries who underwent bilateral dynamic CT imaging of the DRUJ, static 3T MRI, and subsequent wrist arthroscopy. All patients had evidence of foveal tenderness on clinical examination. The imaging results were validated with wrist arthroscopy. Results: Twelve patients with a mean age of 31 years (range, 18-53 years) were identified. Eight patients were diagnosed with a complete foveal detachment of the TFCC on wrist arthroscopy. Of the 8 patients with a foveal tear on DRUJ arthroscopy, only 3 had a preoperative physical examination suggestive of DRUJ instability. Magnetic resonance imaging identified foveal injuries in 4 of these 8 patients (sensitivity, 50%), and 3 of these were identified as only partial tears. Dynamic CT identified instability of DRUJ in 6 of 8 patients (sensitivity, 75%). Seven of 8 patients had imaging findings suggestive of a foveal tear when including either MRI or CT imaging (sensitivity, 88%). Of the 4 patients with an intact foveal attachment on arthroscopy, 3 (specificity, 75%) had a stable DRUJ on CT and all 4 (specificity, 100%) had an intact foveal attachment on MRI. Conclusion: Sixty-two percent of patients with foveal tears on arthroscopy have a stable DRUJ on clinical examination. When combining MRI and dynamic CT imaging of the DRUJ, the sensitivity of detecting a foveal TFCC tear approaches 88% compared with a gold standard of wrist arthroscopy.
The Role of the Built Environment as a Therapeutic Intervention in Mental Health Facilities: A Systematic Literature Review
Authors: Rodríguez-Labajos Laura , Kinloch Joanne , Grant Susan , O’Brien Geraldine 
Published: February 2024

Objectives: This systematic literature review synthesizes and assesses empirical research concerning the use of the built environment as a therapeutic intervention in adult mental health inpatient facilities. The review explores the impact of facility design on patient outcomes. Background: There is a growing recognition that the built environment in mental health facilities must strike a balance between ensuring safety and providing a therapeutic atmosphere. A review addressing how facility design contributes to this therapeutic environment is warranted. Methods: Database searches were conducted in CINAHL, Embase, PsychInfo, PubMed, and Web of Science from inception up to March 10, 2022. The Scottish Intercollegiate Guidelines Network (SIGN50) critical appraisal checklists were used to assess the quality of included studies. Results: Of the 44 peer-reviewed studies identified from nine countries, several factors emerged as vital for the therapeutic environment in mental health inpatient facilities. These included personal spaces prioritizing privacy and control of the environment, daylight-optimized spaces, versatile communal areas promoting activities and interaction, designated areas for visits and spiritual/contemplative reflection, homelike environments, the inclusion of artwork in units, open nursing stations, and dedicated female-only areas. Yet, there is a need for research yielding stronger evidence-based designs harmonizing with therapeutic needs. Conclusion: This review offers initial guidance on designing mental health facilities that foster a therapeutic environment, while highlighting that the influence of facility design on mental health inpatients is considerably under-researched.
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
Authors: Kuter David J. , Mayer Jiri , Efraim Merlin , Bogdanov Lachezar H. , Baker Ross , Kaplan Zane , Garg Mamta , Trněný Marek , Choi Philip Y. , Jansen A. J. Gerard , McDonald Vickie , Bird Robert , Gumulec Jaromir , Kostal Milan , Gernsheimer Terry , Ghanima Waleed , Daak Ahmed , Cooper Nichola 
Published: February 2024

Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia
Authors: Myers Regina M. , Devine Kaitlin , Li Yimei , Lawrence Sophie , Leahy Allison Barz , Liu Hongyan , Vernau Lauren , Callahan Colleen , Baniewicz Diane , Kadauke Stephan , McGuire Regina , Wertheim Gerald B. , Kulikovskaya Irina , Gonzalez Vanessa E. , Fraietta Joseph A. , DiNofia Amanda M. , Hunger Stephen P. , Rheingold Susan R. , Aplenc Richard , June Carl H. , Grupp Stephan A. , Wray Lisa , Maude Shannon L. 
Published: February 2024

Abstract
Relapse after CD19-directed chimeric antigen receptor (CAR)–modified T cells remains a substantial challenge. Short CAR T-cell persistence contributes to relapse risk, necessitating novel approaches to prolong durability. CAR T-cell reinfusion (CARTr) represents a potential strategy to reduce the risk of or treat relapsed disease after initial CAR T-cell infusion (CARTi). We conducted a retrospective review of reinfusion of murine (CTL019) or humanized (huCART19) anti–CD19/4-1BB CAR T cells across 3 clinical trials or commercial tisagenlecleucel for relapse prevention (peripheral B-cell recovery [BCR] or marrow hematogones ≤6 months after CARTi), minimal residual disease (MRD) or relapse, or nonresponse to CARTi. The primary endpoint was complete response (CR) at day 28 after CARTr, defined as complete remission with B-cell aplasia. Of 262 primary treatments, 81 were followed by ≥1 reinfusion (investigational CTL019, n = 44; huCART19, n = 26; tisagenlecleucel, n = 11), representing 79 patients. Of 63 reinfusions for relapse prevention, 52% achieved CR (BCR, 15/40 [38%]; hematogones, 18/23 [78%]). Lymphodepletion was associated with response to CARTr for BCR (odds ratio [OR], 33.57; P = .015) but not hematogones (OR, 0.30; P = .291). The cumulative incidence of relapse was 29% at 24 months for CR vs 61% for nonresponse to CARTr (P = .259). For MRD/relapse, CR rate to CARTr was 50% (5/10), but 0/8 for nonresponse to CARTi. Toxicity was generally mild, with the only grade ≥3 cytokine release syndrome (n = 6) or neurotoxicity (n = 1) observed in MRD/relapse treatment. Reinfusion of CTL019/tisagenlecleucel or huCART19 is safe, may reduce relapse risk in a subset of patients, and can reinduce remission in CD19+ relapse.
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study
Authors: Han Xiaoyu , Chen Lu , Guo Liyan , Wu Linxia , Alwalid Osamah , Liu Jie , Zheng Yuting , Chen Leqing , Wu Wenlong , Li Hanting , Luo Qinyue , Zhao Huangxuan , Zhang Lijie , Bai Yaowei , Sun Bo , Sun Tao , Gui Yuxi , Nie Tong , Chen Lei , Yang Fan , Fan Yanqing , Shi Heshui , Zheng Chuansheng 
Published: February 2024

BackgroundThis study aimed to evaluate the longitudinal progression of residual lung abnormalities (ground-glass opacities, reticulation and fibrotic-like changes) and pulmonary function at 3 years following coronavirus disease 2019 (COVID-19).MethodsThis prospective, longitudinal cohort study enrolled COVID-19 survivors who exhibited residual lung abnormalities upon discharge from two hospitals. Follow-up assessments were conducted at 6 months, 12 months, 2 years and 3 years post-discharge, and included pulmonary function tests, 6-min walk distance (6MWD), chest computed tomography (CT) scans and symptom questionnaires. Non-COVID-19 controls were retrospectively recruited for comparative analysis.Results728 COVID-19 survivors and 792 controls were included. From 6 months to 3 years, there was a gradual improvement in reduced diffusing capacity of the lung for carbon monoxide (DLCO<80% predicted: 49%versus38%; p=0.001), 6MWD (496versus510 m; p=0.002) and residual lung abnormalities (46%versus36%; p<0.001), regardless of disease severity. Patients with residual lung abnormalities at 3 years more commonly had respiratory symptoms (32%versus16%; p<0.001), lower 6MWD (494versus510 m; p=0.003) and abnormalDLCO(57%versus27%; p<0.001) compared with those with complete resolution. Compared with controls, the proportions ofDLCOimpairment (38%versus17%; p<0.001) and respiratory symptoms (23%versus2.2%; p<0.001) were significantly higher in the matched COVID-19 survivors at the 3-year follow-up.ConclusionsMost patients exhibited improvement in radiological abnormalities and pulmonary function over time following COVID-19. However, more than a third continued to have persistent lung abnormalities at the 3-year mark, which were associated with respiratory symptoms and reduced diffusion capacity.
Investigating the synthesis parameters of durian skin-based activated carbon and the effects of silver nanocatalysts on its recyclability in methylene blue removal
Authors: Amir Dzilal , Nasaruddin Ricca Rahman , Yousefi Maryam , Mastuli Mohd Sufri , Sulaiman Sarina , Alam Md. Zahangir , Engliman Nurul Sakinah 
Published: February 2024

AbstractActivated carbon (AC) is the most common and economically viable adsorbent for eliminating toxic organic pollutants, particularly dyes, from wastewater. Its widespread adoption is due to the simplicity and affordable production of AC, wherein low-cost agricultural wastes, such as durian skin can be used. Converting durian skin into AC presents a promising solution for its solid waste management. However, inherent drawbacks such as its non-selectivity, relatively short lifespan and laborious replacement and recovery processes diminish the overall efficacy of AC as an adsorbent. To address these challenges, the immobilisation of metal nanocatalysts such as silver nanoparticles (AgNPs) is one of the emerging solutions. AgNPs can facilitate the regeneration of the adsorption sites of AC by catalysing the conversion of the adsorbed dyes into harmless and simpler molecules. Nevertheless, the immobilisation of AgNPs on AC surface can be challenging as the pore size formation of AC is hard to control and the nanomaterials can easily leach out from the AC surface. Hence, in this study, we synthesised AC from durian skin (DS) and immobilised AgNPs on the AC-DS surface. Then, we used methylene blue (MB) removal for studying the adsorption capability and recyclability of the AC-DS. In the synthesis of AC-DS, the influences of reaction temperature, activating agent, and acid-washing to its capability in adsorptive removal of MB in solution were first determined. It was found that 400 °C, KOH activating agent, and the presence of acid-washing (50% of HNO3) resulted in AC-DS with the highest percentage of MB removal (91.49 ± 2.86%). Then, the overall results from three recyclability experiments demonstrate that AC-DS with immobilised AgNPs exhibited higher MB removal after several cycles (up to 6 cycles) as compared to AC-DS alone, proving the benefit of AgNPs for the recyclability of AC-DS. We also found that AgNPs/Citrate@AC-DS exhibited better adsorption capability and recyclability as compared to AgNPs/PVP@AC-DS indicating significant influences of type of stabilisers in this study. This study also demonstrates that the presence of more oxygen-containing functional groups (i.e., carboxyl and hydroxyl functional groups) after acid-washing on AC-DS and in citrate molecules, has greater influence to the performance of AC-DS and AgNPs/Citrate@AC-DS in the removal of MB as compared to the influences of their BET surface area and pore structure. The findings in this study have the potential to promote and serve as a guideline for harnessing the advantages of nanomaterials, such as AgNPs, to enhance the properties of AC for environmental applications.
Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients
Authors: Kaneko Tomonori , Ezra Sally , Abdo Rober , Voss Courtney , Zhong Shanshan , Liu Xuguang , Hovey Owen , Slessarev Marat , Van Nynatten Logan Robert , Ye Mingliang , Fraser Douglas D. , Li Shawn Shun-Cheng 
Published: February 2024

AbstractSARS-CoV-2 infection triggers extensive host immune reactions, leading to severe diseases in certain individuals. However, the molecular basis underlying the excessive yet non-productive immune responses in severe COVID-19 remains incompletely understood. In this study, we conducted a comprehensive analysis of the peripheral blood mononuclear cell (PBMC) proteome and phosphoproteome in sepsis patients positive or negative for SARS-CoV-2 infection, as well as healthy subjects, using quantitative mass spectrometry. Our findings demonstrate dynamic changes in the COVID-19 PBMC proteome and phosphoproteome during disease progression, with distinctive protein or phosphoprotein signatures capable of distinguishing longitudinal disease states. Furthermore, SARS-CoV-2 infection induces a global reprogramming of the kinome and phosphoproteome, resulting in defective adaptive immune response mediated by the B and T lymphocytes, compromised innate immune responses involving the SIGLEC and SLAM family of immunoreceptors, and excessive cytokine-JAK-STAT signaling. In addition to uncovering host proteome and phosphoproteome aberrations caused by SARS-CoV-2, our work recapitulates several reported therapeutic targets for COVID-19 and identified numerous new candidates, including the kinases PKG1, CK2, ROCK1/2, GRK2, SYK, JAK2/3, TYK2, DNA-PK, PKCδ, and the cytokine IL-12.
Treatment effect estimation using the propensity score in clinical trials with historical control
Authors: Kanamori Saki , Takeuchi Masahiro 
Published: February 2024

Abstract
Background
Clinical trials assessing new treatment effects require a control group to compare the pure treatment effects. However, in clinical trials on regenerative medicine, rare diseases, and intractable diseases, it may be ethically difficult to assign participants to the control group. In recent years, the use of historical control data has attracted attention as a method for supplementing the number of participants in the control group. When combining historical control data with new randomized controlled trial (RCT) data, the assessment of heterogeneity using outcome data is not sufficient. Therefore, several statistical methods that consider participant outcomes and baseline characteristics, including the propensity score (PS) method have been proposed.

Methods
We propose a new method considering “information on whether the data are RCT data or not” in the PS model when combining the RCT and historical control data. The performance of the proposed method in estimating the treatment effect is evaluated using simulation data.

Results
When the distribution of covariates is similar between the RCT and historical control data, not much difference in performance is found between the proposed and conventional methods to estimate the treatment effect. On the other hand, when the distribution of covariates is not similar between the two kinds of data, the proposed method shows higher performance.

Conclusions
Even when it is not known whether RCT and historical control data are similar, the proposed PS model is useful to estimate the treatment effect appropriately in RCTs using historical control data.
The experience of feeling old after a fragility fracture
Authors: Sale Joanna E.M. , Frankel Lucy , Bogoch Earl , Carlin-Coleman Gabriel , Hui Sean , Saini Jessica , McKinlay Jennifer , Meadows Lynn 
Published: February 2024

Abstract
Background
There has been little exploration of the effect of fragility fractures on patient perceptions of their age. The common assumption is that fractures “happen to old people”. In individuals with a fragility fracture, our objective was to explore the experience of feeling old after sustaining a fragility fracture.

Methods
A secondary analysis of data from 145 community-dwelling women and men participating in six qualitative primary studies was conducted relying on a phenomenological approach. Participants were English-speaking, 45 years and older, who had sustained a recent fragility fracture or reported a history of previous fragility fractures. Data for the analysis included direct statements about feeling old as well any discussions relevant to age post-fracture.

Results
We highlight two interpretations based on how individuals with a history of fragility fracture talked about age: (1) Participants described feeling old post-fracture. Several participants made explicit statements about being “old”. However, the majority of participants discussed experiences post-fracture that implied that they felt old and had resigned themselves to being old. This appeared to entail a shift in thinking and perception of self that was permanent and had become a part of their identity; and (2) Perceptions of increasing age after sustaining a fracture were reinforced by health care providers, family, and friends.

Conclusions
Our findings challenge the notion that fractures “happen to old people” and suggest that fractures can make people feel old. Careful consideration of how bone health messages are communicated to patients post-fracture by health care providers is warranted. (Word Count: 248)